Lava Therapeutics N.V. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment
The company specializes in its unique platform technology aimed at harnessing the power of gamma delta T cells, a type of immune cell that plays a significant role in the body’s defense against tumors. By creating novel immune-oncology treatments, Lava Therapeutics strives to improve patient outcomes and provide more effective options for those battling various forms of cancer. Through rigorous research and development, the company seeks to advance its product pipeline and bring new therapies to market, aiming to address unmet medical needs in the oncology space.
Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose 0.37% to 15,538.69. The S&P 500 also rose, gaining, 0.40% to 4,887.88.
Gainers MultiMetaVerse Holdings Limited (NASDAQMMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.
Gainers Better Choice Company Inc. (NASDAQBTTR) shares rose 37% to $0.4522 in pre-market trading. Better Choice said it has selected Re:Amaze to assist in customer retention and acquisition for its Halo Brand of dog and cat food.
Gainers Vallon Pharmaceuticals, Inc. (NASDAQVLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Gainers Crown ElectroKinetics Corp. (NASDAQCRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Piper Sandler raised Snap Inc. (NYSESNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
